Dowload ASPR Strategic Plan FY 2026-2029 The Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) has released its Strategic Plan for Fiscal Years (FY) 2026–2029, setting a clear direction for the federal government’s approach to health security. As the nation’s lead health security agency, ASPR is responsible for preparing […]
ASPR’s Strategic Plan for FY 2026-2029 Read More »
New-Vaccine-Platforms-RFI_Amd-1.pdf The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has released a new Request for Information (RFI) focused on “New Vaccine Platforms.” This solicitation seeks to better understand the current landscape of vaccine platform technologies
BARDA Seeks Next-Generation Vaccine Platforms to Accelerate National Preparedness Read More »
RPPV-26-07-ASSURE-Amendment-2 The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the Rapid Response Partnership Vehicle (RRPV): the Assay Development for Superior Understanding of Response and Efficacy (ASSURE) program. Designed to strengthen national health security, ASSURE seeks to accelerate the development
BARDA’s ASSURE Program to Advance Next-Generation Immune Assays Read More »
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has released a new Sources Sought Notice (SSN) and Request for Information (RFI) focused on vaccine medical countermeasures (MCMs) for pandemic influenza preparedness and response. This initiative underscores BARDA’s ongoing commitment to strengthening the nation’s biosecurity
BARDA Seeks Industry Input for Pandemic Influenza Vaccine Partnerships Read More »
BARDA RAPID RFI RAPID Overview The Biomedical Advanced Research and Development Authority (BARDA) has issued a new Request for Information (RFI) titled “Rapid Antibody Production for Immunoassay Diagnostics (RAPID)”. Through this RFI, BARDA seeks to more deeply understand causes of existing bottlenecks in the antibody generation process (design through production) and assess the R&D landscape
BARDA’s RAPID RFI for Next-Generation Antibody Design through Production Read More »
BARDA RRPV-26-09-AgDx Request for Project Proposals The Biomedical Advanced Research and Development Authority (BARDA) has released a new Request for Project Proposals (RPP-26-09-AgDx) through the Rapid Response Partnership Vehicle (RRPV), seeking to revolutionize the nation’s diagnostic readiness for infectious disease threats. Managed by Advanced Technology International (ATI), the RRPV enables collaboration between industry, academia, and
Advancing Pathogen-Agnostic Diagnostics Read More »
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has issued a new Request for Project Proposals (RPP-26-10-VHF) under its Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). This solicitation represents a key step in building domestic capacity for advanced vaccine manufacturing to strengthen the nation’s biosecurity infrastructure.
BARDA’s RPP to Onshore Vaccine Manufacturing for Viral Hemorrhagic Fevers Read More »
When the federal government faces a lapse in appropriations, agencies across the Department of Health and Human Services (HHS) must implement contingency plans to sustain critical activities. Both the Advanced Research Projects Agency for Health (ARPA-H) and the Administration for Strategic Preparedness and Response (ASPR), which houses the Biomedical Advanced Research and Development Authority (BARDA),
HHS Operations During A Government Shutdown Read More »
Driving Innovation in Antibody Manufacturing The Biomedical Advanced Research and Development Authority (BARDA) has launched a new Request for Project Proposals (RPP) aimed at transforming the speed, efficiency, and resilience of antibody (Ab) production. Issued under the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), the initiative seeks to integrate advanced manufacturing technologies into Ab production systems to
BARDA Issues New RPP to Advance Smart Manufacturing for Antibodies Read More »
Background The Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) has released a Draft Statement of Objectives (SOO) for feedback to help refine requirements for the upcoming “Smart Manufacturing” solicitation aiming to support the development of advanced monoclonal antibody (mAb) manufacturing and development techniques. The solicitation’s overarching
BARDA’s mAb “Smart Manufacturing” Opportunity Read More »
As the global health landscape evolves, so too must the United States’ ability to respond rapidly to biological threats. To strengthen its readiness posture, the Biomedical Advanced Research and Development Authority (BARDA), in coordination with the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the BioMaP Consortium OT Vehicle. This
BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates Read More »
BARDA RFP – Enzymatic Debridement Products for Treatments of Deep and Full- Thickness Severe Burn Injuries – 75A50125R00007 – Amendment 0001 The Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), has released a significant new opportunity to strengthen national preparedness for burn mass casualty
BARDA Solicits Enzymatic Debridement Solutions Read More »
